CXCR3 and neoplasm: Moreover, when we evaluated the efficacy of regorafenib at 10 mg/kg with anti-PD1 antibody treatment in Cxcr3–/– mice in survival experiments, we found no additional survival benefit for this combination over anti-PD1 therapy alone (figure 5C); these data are in contrast to the benefits seen with regorafenib at 10 mg/kg with anti-PD1 antibody treatment in Cxcr3+/+ tumor-bearing mice (figure 4C).